Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207347 · ClinicalTrials.gov registry record · Phase 2
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
A Phase 2 study of Renal Cell Carcinoma and Cholangiocarcinoma, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 3
- Study locations
NCT03207347 is a Phase 2 study of Renal Cell Carcinoma and Cholangiocarcinoma that has completed, run by University of Florida. The registered enrollment target is 37 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03207347, a Phase 2 study of Renal Cell Carcinoma and Cholangiocarcinoma, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 3
- Study locations
Study Summary
This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
Conditions Studied
Interventions
- DRUG Niraparib
Study Locations (3)
Florida
- University of Florida - Gainesville
- University of Miami - Miami
- Orlando Health UF Health Cancer Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03207347
The ClinicalTrials.gov registry entry for NCT03207347 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (85% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Niraparib is the first listed.
NCT03207347 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03207347 about?
NCT03207347 is a clinical study titled "A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)". This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
What is the current status of trial NCT03207347?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2018-08-13. Estimated completion is 2022-08-30.
What conditions does trial NCT03207347 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Cholangiocarcinoma, Mesothelioma, Uveal Melanoma.
What interventions are being tested in trial NCT03207347?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT03207347?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03207347 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.